Document Type

Article

Publication Date

2015

DOI

10.1179/2047773215y.0000000028

Publication Title

Pathogens and Global Health

Volume

109

Issue

6

Pages

275-282

Abstract

We conducted a randomised single-blinded clinical trial of 100 cholera patients in Port-au-Prince, Haiti to determine if the probiotic Saccharomyces cerevisiae var. boulardii and the anti-diarrhoeal drug bismuth subsalicylate (BS) were able to reduce the duration and severity of cholera. Subjects received either: S. boulardii 250 mg, S. boulardii 250 mg capsule plus BS 524 mg tablet, BS 524 mg, or two placebo capsules every 6 hours alongside standard treatment for cholera. The length of hospitalisation plus the number and volume of emesis, stool and urine were recorded every 6 hours until the study subject was discharged (n=83), left against medical advice (n=11), or requested removal from the study (n=6). There were no reported deaths or adverse study-related events. There were no statistically significant differences between the study arms and the outcomes of interest.

Comments

Green Published open access on Web of Science.

Original Publication Citation

Sheele, J., Cartowski, J., Dart, A., Poddar, A., Gupta, S., Stashko, E., . . . Gupta, A. (2015). Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera. Pathogens and Global Health, 109(6), 275-282. doi:10.1179/2047773215y.0000000028

Download

Share

COinS